Validation of B-COMPASSS

The study is designed to reflect the real heterogeneity of patients, diseases, healthcare contexts and geographies that B-COMPASS is meant to serve.

3500

patients participating

18

settings & organisations

Disease areas under study

Cardiology

Endocrinology

Immunology​

Oncology​

Neurology​

Rare Disease

Data collection settings

Geographical reach

EU Pilot Sites

Czech Republic

Germany

Greece

Italy

Netherlands

Norway

Portugal

Slovaneia

Spain

Non-EU Pilot Sites

Brazil

Mexico

Tanzania

USA

Canada

Japan

Study design & patient participation

1. Initial data collection
  • Patients complete the BEAMER questionnaire, capturing actionable behavioural factors affecting treatment adherence.
  • A baseline adherence measurement is taken.
  • Patients are assigned to a B-COMPASS group based on key behavioural factors:
  • Segmentation of actionable behavioural factors
  • Predicted risk of non-adherence
2. Randomisation
  • Patients are randomised into two arms:

Intervention
  • Standard care plus enhanced engagement based on their B-COMPASS group.

Control
  • Standard care only.
3. Second data collection
  • Patients complete the BEAMER questionnaire again.
  • Adherence is re-measured to assess change.
  • Contextual data is collected (e.g. events affecting adherence).
  • Patients share their experience of enhanced engagement from healthcare providers, beyond standard care.

The study is designed to reflect the real heterogeneity of patients, diseases, healthcare contexts and geographies that B-COMPASS is meant to serve.

Purpose of data collection

Validate the B-COMPASS

Benefits for patients

Intervention group

Both groups

Long-term impact

Explaining the validation of B-COMPASS

Download the full infographic summarising the study design, participation and patient benefits.